#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Rosai-Dorfman syndrome Rett syndrome Ocular myasthenia Cataract Endometrial cancer recurrent Cystic fibrosis respiratory infection suppression Myelin oligodendrocyte glycoprotein antibody-associated disease Congenital cystic kidney disease Primary hyperoxaluria Small intestine leiomyosarcoma Liver transplant rejection Leber's congenital amaurosis Ovarian cancer Germ cell cancer Cardiac sarcoidosis More trials…

    Learn about Rare Diseases

    Glomerulonephritis membranoproliferative – Trials in Disease Lymphangiosarcoma – Trials in Disease Paroxysmal nocturnal haemoglobinuria Prader-Willi syndrome Waldenstrom’s macroglobulinaemia refractory – Diagnostics Isodicentric chromosome 15 syndrome – Diagnostics Idiopathic inflammatory myopathy – Trials in Disease Alagille syndrome – Treatment Small intestine leiomyosarcoma Optic glioma – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    GSK4418959A Tramazoline Hydrochloride Sodium Chloride Ziprasidone Autogene Cevumeran Vatiquinone Tucidinostat Urapidil Resatorvid Ep0042 Amiodarone Hydrochloride Sodium Laurilsulfate Caplacizumab Etifoxine Hydrochloride Ucart20X22 LY3537031 [99MTC]PSMA I&S Ibuprofen Lysine Azilsartan Medoxomil Pp1493 More therapies…

    Learn about Your Condition

    Wiskott-Aldrich syndrome Ependymoma malignant Mesothelioma malignant Retinal artery occlusion Small intestine carcinoma Status epilepticus Hypertonic bladder Spinal muscular atrophy Hypotransferrinaemia Cough Haemorrhagic stroke Bipolar disorder Vasospasm Anal cancer stage III Neurotrophic keratopathy More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Rheumatoid arthritis

  • Study Comparing Methotrexate or Leflunomide with Targeted Therapy vs. Methotrexate or Leflunomide with Drug Combination for Rheumatoid Arthritis Patients

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Rheumatoid arthritis
    Investigated Drugs:
    • Leflunomide
    • Sulfasalazine
    • Hydroxychloroquine Sulfate
    France

  • Evaluation of Two Prednisolone Treatment Strategies for Newly Diagnosed, Untreated Rheumatoid Arthritis Patients

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Rheumatoid arthritis
    Investigated Drugs:
    • Prednisolone
    Sweden

  • A long-term safety study of KYV-101 in patients previously treated for lupus nephritis, systemic sclerosis, myasthenia gravis, rheumatoid arthritis, or stiff person syndrome

    Recruiting

    4 1 1
    Investigated Drugs:
    • Kyv-101
    Germany

  • Methotrexate tapering versus usual care in elderly (≥70) patients with rheumatoid arthritis in low disease activity – drug combination study

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    • Rheumatoid arthritis
    Investigated Drugs:
    • Leflunomide
    • Sulfasalazine
    • Hydroxychloroquine Sulfate
    Denmark

  • Effect of High‑Dose Thiamine Hydrochloride on Fatigue in Rheumatoid Arthritis Patients: Randomized, Double‑Blind, Placebo‑Controlled Trial

    Not yet recruiting

    3 1 1
    Investigated Diseases:
    • Rheumatoid arthritis
    Investigated Drugs:
    • Thiamine Hydrochloride
    Denmark

  • ELV001 for Active Rheumatoid Arthritis in Patients with Inadequate Response to Methotrexate and Tumor Necrosis Factor Inhibition

    Not yet recruiting

    2 1
    Bulgaria Czechia Hungary The Netherlands Poland Spain
Previous Page
1 … 3 4 5 6 7 … 12
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!